![]() On a proforma basis, the combined business generated C$11.9 million of annual revenues (trailing four quarters reported, as at June 10, 2022). The transaction has also provided a strong US platform for potential continued growth in partnership and acquisition opportunities. Numinus and Novamind clients will benefit from access to a greater variety of services and treatments over the coming months, including the expansion of virtual therapy services at US-based clinics and increased group therapy offerings in Canada. This acquisition significantly grows Numinus' client service offerings, geographic reach, and revenues. As a result of the acquisition, Numinus now operates 13 wellness clinics, four clinical research facilities and a dedicated psychedelics research lab – positioning the company as a leading integrated mental wellness company providing ketamine- and psychedelic-assisted therapies. ("Novamind") has completed, following Novamind's receipt of a final order from the BC Supreme Court. ("Numinus", the "Company") (TSX: NUMI) (OTCQX: NUMIF) is pleased to announce the acquisition (the "Transaction") of Novamind Inc. Michael Tan has been promoted to President and Chief Operating Officer.Reid Robison has been appointed Chief Clinical Officer and Paul Thielking has been appointed Chief Science Officer. ![]() As a result of the acquisition, Novamind has ceased trading on the Canadian Securities Exchange (CSE).Novamind shareholders and RSU holders have been issued 0.84 Numinus shares per Novamind share.Transaction has completed following shareholder and court approvals. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |